RegionInternational. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Explore  /  Cerebrolysin
Research reference — not for sale

Cerebrolysin

C
lead outcome
Vascular dementia
grades vary by outcome ↓
Peptide
also called — Cerebrolysin · a porcine brain-derived neuropeptide preparation
neuroprotectionstroke recoveryTBIvascular dementia / Alzheimer's(nootropic, in gray-market framing)

The most-studied cognitive "peptide" — approved in 50+ countries, yet its evidence is genuinely contested. Three points define this entry: (1) it's not a single peptide but a porcine (pig) brain extract — a mixture of neuropeptides and amino acids; (2) it has by far the largest human evidence base of any nootropic peptide (160+ trials, 8000+ patients) and is approved/registered in 50+ countries — but not FDA-approved; (3) despite that, Cochrane reviews across three decades keep finding the evidence weak (small samples, bias, manufacturer funding), and a 2023 Cochrane review flagged a rise in serious adverse events. It's the register's cleanest "widely used, still unproven" case.

In brief

Cerebrolysin is a pig-brain-derived mixture of neuropeptides and amino acids (not a single molecule), given by IV/IM, that mimics the brain's own neurotrophic factors (BDNF, NGF, GDNF) to support neuron survival and synaptic plasticity. It's the most clinically-studied "cognitive peptide" by a wide margin — 160+ trials, 8000+ patients, and approval in 50+ countries for stroke, TBI, and dementia — with individual RCTs (e.g. CASTA in stroke; several Alzheimer's trials) showing real cognitive/functional benefits, and the vascular-dementia evidence among its strongest. But the evidence is genuinely contested: Cochrane reviews across three decades rate it low-quality (small samples, high bias, heavily manufacturer-funded), there's no independent confirmation, a 2023 Cochrane found no mortality benefit and a significant rise in serious adverse events in acute stroke, and it is not FDA-approved. So the honest read is unusual for this register: lots of human data and real-world approval — but quality and independence problems keep Western academic neurology cautious. Big evidence base ≠ settled evidence.

Legal standing, by region
European Union
Status varies

status varies by country; it is a prescription medical product where registered, not a cosmetic and not a self-administered supplement.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Vascular dementia
Among the better-supported uses — but Cochrane still cautious; manufacturer funding pervasive
Multiple RCTs + 2020 systematic review (J Neural Transm); often cited as its strongest indication
C
Alzheimer's disease (cognition)
Positive signal, but short follow-up, small trials, industry-sponsored; Cochrane "very low" quality
Meta-analysis of 6 double-blind placebo-controlled trials: significant vs placebo at 4 wk, effect size ~ cholinesterase inhibitors
C
Stroke recovery (cognitive/functional)
Individual trials positive; 2023 Cochrane: no mortality benefit + ↑ serious AEs (RR ~2.39); 2012 trial doubted benefit except severe cases
CASTA (1,070 pts): improved 90-day cognition; several rehab RCTs
C
Traumatic brain injury (TBI)
Suggestive; smaller/heterogeneous evidence
RCTs + 2025 mechanistic work on secondary-injury modulation
C
Nootropic use in healthy adults (the gray-market use)
No evidence it helps healthy cognition or prevents dementia; extrapolation from patient data is unjustified
Essentially none — trials are in disease populations
F
Independent replication / overall quality
The core problem: predominantly manufacturer-funded, high risk of bias, no independent confirmation. Large ≠ high-quality
Three decades of Cochrane appraisal
Safety
Generally described as safe short-term; porcine allergy = absolute contraindication; rare seizure reports (causality unclear); caution with serotonergic antidepressants; 2023 Cochrane flagged ↑ non-fatal serious AEs
Large exposure across trials/clinical use
Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Cerebrolysin changes - nothing else.

One ingredient, one purpose. No marketing, no sharing. Unsubscribe anytime. See our privacy policy.

Identity

unlike every other entry here, Cerebrolysin is not one molecule. It's a proprietary extract from purified pig-brain tissue, produced by controlled enzymatic hydrolysis, yielding a standardized mixture of low-molecular-weight neuropeptides and free amino acids. The low-MW fragments are small enough to cross the blood-brain barrier. It is given only by IV infusion or IM injection (peptides would be digested if taken orally). Made exclusively by EVER Neuro Pharma (Austria).

Mechanism (as proposed)

Cerebrolysin's low-molecular-weight peptide fragments are thought to cross the blood-brain barrier and mimic endogenous neurotrophic factorsBDNF, NGF and GDNF — thereby supporting neuronal survival, synaptic plasticity, neurogenesis, and reducing secondary injury processes (astrogliosis, axonal injury in animal models). Because it's a mixture, the effect is described as multimodal (neurotrophic-like + neuroprotective + possibly synaptogenic) rather than a single receptor action. This "brain-cocktail mimicking growth factors" framing is biologically plausible and animal-supported — but the clinical translation is exactly what remains contested.

Sources — 5 cited
01Cochrane reviews — Cerebrolysin for vascular dementia (2013; updated 2025) and for acute ischemic stroke (2023, 7 RCTs / 1,773 participants: no mortality benefit; ↑ non-fatal serious AEs RR ~2.39).
02Heiss WD, et al. Cerebrolysin in acute ischemic stroke in Asia (CASTA). Stroke. 2012.
03Alvarez XA, Cacabelos R, et al. — Alzheimer's RCTs (24-week dose-ranging; combination with donepezil).
042020 systematic review, J Neural Transm (vascular dementia); Thome & Doppler (2012) safety profile.
05EVER Neuro Pharma (manufacturer) — composition/administration. (Note: evidence base is large but predominantly manufacturer-funded; no independent confirmation as of 2026.)
Updated 2026-07-13 (watch for the updated 2025 Cochrane vascular-dementia review and any independent, non-industry RCT — that would be decisive)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
SemaxC
Peptide
SelankC
Peptide
Dihexa (PNB-0408)F
Peptide
Explore by goal
Neuro & cognitive
Vallydia

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

RegionInternational
ExploreRegisterThe Register — full indexCategoriesTrust & COAHow we gradeOpen dataBrands
ShopCosmetic peptidesJournalQuizzes
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.